Manel Jendoubi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Manel Jendoubi has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- David Launay
CHU de Lille, Service de Médecine Interne et Immunologie Clinique, Centre de référence des Maladies Auto-Immunes et Auto-inflammatoires Systémiques rares de l'Adulte du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), 59000 Lille, France; U1286-INFINITE-Institute for Translational Research in Inflammation, Université de Lille, 59000 Lille, France; Inserm, 59000 Lille, France
2 shared publications - Eric Hachulla
Département de Médecine Interne et Immunologie Clinique, CHU Lille, Lille, France
2 shared publications - Silvia Speca
U1286 INFINITE (Institute for Translational Research in Inflammation), Inserm, CHU Lille, Université de Lille, 59000 Lille, France
2 shared publications - Sylvain Dubucquoi
Institut d’Immunologie, Pôle de Biologie Pathologie Génétique Médicale, CHU Lille, F-59000 Lille, France
2 shared publications - Thomas Guerrier
University of Lille, Inserm, CHU Lille, U1286-INFINITE—Institute for Translational Research in Inflammation, Lille, France
2 shared publications - Vincent Sobanski
Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation
2 shared publications
Latest Publications
- Open Access
- 12 September 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-12
Intravenous immunoglobulins improve skin fibrosis in experimental models of systemic sclerosis
Systemic sclerosis (SSc) is the most severe systemic autoimmune disease with currently no cure. Intravenous immunoglobulins (IVIg) are an attractive candidate in this disease to counteract inflammation and fibrosis but data are scarce and conflicting. This study, assessed the effects of IVIg in a murine HOCl-induced model of SSc. We showed that IVIg prevented skin inflammation and fibrosis, by mitigating the immune cell infiltration (p = 0.04), proinflammatory cytokines gene overexpression (IL1β, p = 0.04; TNFα, p = 0.04; IL6, p = 0.05), skin and dermal thickening (p = 0.003 at d21 and p = 0.0003 at d42), the expression markers of fibrosis, such as αSMA (p = 0.031 for mRNA and p = 0.05 for protein), collagen (p = 0.05 for mRNA and p = 0.04 for protein, p = 0.05 for the hydroxyproline content) and fibronectin (p = 0.033 for mRNA). Moreover, IVIg prevented HOCl-induced alterations in splenic cell homeostasis. When administered in curative mode, despite their ability to reduce skin and dermal thickness (p < 0.0001 and p = 0.0002), IVIg showed partial or more mixed effects on skin inflammation and established fibrosis. These data favor further clinical trials in SSc patients on the potential efficiency of early and/or repeated IVIg administration.
- 12 September 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-12
Open AccessIntravenous immunoglobulins improve skin fibrosis in experimental models of systemic sclerosis
Systemic sclerosis (SSc) is the most severe systemic autoimmune disease with currently no cure. Intravenous immunoglobulins (IVIg) are an attractive candidate in this disease to counteract inflammation and fibrosis but data are scarce and conflicting. This study, assessed the effects of IVIg in a murine HOCl-induced model of SSc. We showed that IVIg prevented skin inflammation and fibrosis, by mitigating the immune cell infiltration (p = 0.04), proinflammatory cytokines gene overexpression (IL1β, p = 0.04; TNFα, p = 0.04; IL6, p = 0.05), skin and dermal thickening (p = 0.003 at d21 and p = 0.0003 at d42), the expression markers of fibrosis, such as αSMA (p = 0.031 for mRNA and p = 0.05 for protein), collagen (p = 0.05 for mRNA and p = 0.04 for protein, p = 0.05 for the hydroxyproline content) and fibronectin (p = 0.033 for mRNA). Moreover, IVIg prevented HOCl-induced alterations in splenic cell homeostasis. When administered in curative mode, despite their ability to reduce skin and dermal thickness (p < 0.0001 and p = 0.0002), IVIg showed partial or more mixed effects on skin inflammation and established fibrosis. These data favor further clinical trials in SSc patients on the potential efficiency of early and/or repeated IVIg administration.
- 19 October 2021
- Published by Wiley in Proteomics
- Vol. 22 (3) , 2100116
Passages in culture and stimulation conditions influence protein expression of primary fibroblasts
Fibroblasts (Fb) are key effector cells in systemic sclerosis (SSc). Fb stimulation with transforming growth factor beta 1 (TGF‐β1) is considered as a positive control in studies assessing fibrogenesis. The lack of standardization of TGF‐β1 stimulation might be responsible for discrepancies in experiments performed in different conditions. Using quantitative proteomics analysis, we evaluated the impact of changes in experimental conditions on proteomic profiles of primary Fb. Principal component analysis (PCA) identified several groups of differentially expressed proteins influenced by cell passage, culture medium, and both concentration and duration of exposure to TGF‐β1 stimulation. Bioinformatics analysis revealed that late passages expressed proteins involved in senescence. TGF‐β1 concentration and time of stimulation were correlated with the expression of proteins involved in the fibrogenesis and inflammatory processes. These data underline the need for standardization of culture conditions to allow inter‐data comparisons in future in vitro studies, especially when using “omics” approaches.
- 19 October 2021
- Published by Wiley in Proteomics
- Vol. 22 (3) , 2100116
Passages in culture and stimulation conditions influence protein expression of primary fibroblasts
Fibroblasts (Fb) are key effector cells in systemic sclerosis (SSc). Fb stimulation with transforming growth factor beta 1 (TGF‐β1) is considered as a positive control in studies assessing fibrogenesis. The lack of standardization of TGF‐β1 stimulation might be responsible for discrepancies in experiments performed in different conditions. Using quantitative proteomics analysis, we evaluated the impact of changes in experimental conditions on proteomic profiles of primary Fb. Principal component analysis (PCA) identified several groups of differentially expressed proteins influenced by cell passage, culture medium, and both concentration and duration of exposure to TGF‐β1 stimulation. Bioinformatics analysis revealed that late passages expressed proteins involved in senescence. TGF‐β1 concentration and time of stimulation were correlated with the expression of proteins involved in the fibrogenesis and inflammatory processes. These data underline the need for standardization of culture conditions to allow inter‐data comparisons in future in vitro studies, especially when using “omics” approaches.